Replies to post #8623 on Biotech Values

[DewDiligence]

Thanks for the clarification.

[walldiver]

I think two questions important to find answers to for any cancer vaccine are:

1. How soon after agreeing to the treatment does the patient receive the product? With Provenge it is 48-72 hours

2. Is the vaccine autologous or allogenic? Provenge is autologous

I think these are two significant advantages for Provenge in any head-to-head survival study with another vaccine, if Provenge is first to market.

[io_io]

Urche:

"I think DNDN is a good bet as an investment, but I have scientific doubts about the long-term prospects for Provenge."

That seems to be a contradiction. Somewhere I read that 30%-40% of men aged 70 show evidence of PC. Can't see how you like DNDN while doubting "long-term prospects for Provenge".